Rexahn Pharmaceuticals, Inc. (REXN)

[surf1944]

Rexahn Pharmaceuticals Reports Enrollment Progress on Phase IIb Clinical Trial of Serdaxin for Depression

Press Release Source: Rexahn Pharmaceuticals, Inc. On Thursday May 5, 2011, 8:00 am

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled two-thirds of the total patients needed for its Phase IIb clinical trial to study the safety and efficacy of Serdaxin® to treat major depressive disorder (MDD). The Company began enrollment in January 2011 and plans to enroll a total of 300 patients. The trial is being conducted at 40 sites in the United States.

"Serdaxin’s Phase IIb clinical trial enrollment is on schedule, and we are on track to report preliminary results by the end of this year," said Rick Soni, President of Rexahn.

The Serdaxin Phase IIb clinical trial is designed as a randomized, double blind, placebo-controlled study with three treatment arms. The primary endpoint is the change from baseline on the Montgomery-Asberg Depression Rating Scale ("MADRS").